At 10 years, treatment with leuprorelin did not significantly improve OS (89.1% vs 88.9%) or disease-specific survival (98.6% vs 96.5%) compared with observation. The administration of leuprorelin ...

Mutational burden among patients with metastatic prostate cancer differs by race in 3 key genes: An analysis of genomic and clinical data from the AACR Project GENIE biopharma collaborative in ...

Socioeconomic status and concomitant diseases in patients with prostate cancer. 0-6 94,4; n=504 0,40 [0,10-1,31]; n= 512 0,21 [0,10-0,49]; n=81 55-60 90,6; n=476 0,17 [0,05-0,91]; n= 516 0,20 ...

New Delhi, Nov 14 (PTI) Zydus Lifesciences Ltd on Friday said it has received final approval from the US health regulator for its generic version of Leuprolide Acetate injection used in palliative ...

Leuprolide acetate for injection is used to treat the symptoms associated with advanced prostate cancer by way of palliative treatment of advanced prostatic cancer. Aurobindo’s subsidiary, Eugia ...

CHICAGO, June 07, 2019 (GLOBE NEWSWIRE) -- Tolmar Pharmaceuticals Inc., a fully integrated specialty pharmaceutical company, today announced new formulary placement for ELIGARD ® with Rite-Aid’s ...

Cipla is introducing leuprolide acetate injection depot, 22.5 mg, which is the generic of AbbVie’s Lupron Depot. It is indicated for palliative treatment of advanced prostate cancer. Leuprolide ...

Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer. Leuprolide Acetate injections will be manufactured at the Company's oncology injectable ...

Read the Medication Guide provided by your pharmacist before you start using leuprolide and each time you get a refill. If you have any questions, ask your doctor or pharmacist. This medication is ...

MUMBAI, India and WARREN, N.J., Nov. 29, 2022 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and its wholly owned subsidiary Cipla USA Inc. (hereafter referred to as 'Cipla'), today ...